The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Abstract
The aim of this study was to compare the effects of the genetic and pharmacological disruption of CB1 cannabinoid receptors on the elevated plus‐maze test of anxiety. In the first experiment, the behaviour of CB1‐knockout mice and wild‐type mice was compared. In the second experiment, the cannabinoid antagonist SR141716A (0, 1, and 3 mg/kg) was administered to both CB1‐knockout and wild type mice. Untreated CB1‐knockout mice showed a reduced exploration of the open arms of the plus‐maze apparatus, thus appearing more anxious than the wild‐type animals, however no changes in locomotion were noticed. The vehicle‐injected CB1‐knockout mice from the second experiment also showed increased anxiety as compared with wild types. Surprisingly, the cannabinoid antagonist SR141716A reduced anxiety in both wild type and CB1 knockout mice. Locomotor behaviour was only marginally affected. Recent evidence suggests the existence of a novel cannabinoid receptor in the brain. It has also been shown that SR141716A binds to both the CB1 and the putative novel receptor. The data presented here supports these findings, as the cannabinoid receptor antagonist affected anxiety in both wild type and CB1‐knockout mice. Tentatively, it may be suggested that the discrepancy between the effects of the genetic and pharmacological blockade of the CB1 receptor suggests that the novel receptor plays a role in anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which in turn give rise to an anxious/depressive phenotype20, 21.”
From Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study (2013) · cites this paper as [20]
Citations
Cites
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Self-citationA review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety
Hogg, S. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02126-4 · Cited by 1,169
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. M., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, É., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14136 · Cited by 597
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Marzo, V. D., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 538
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martín, M., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 525
Self-citationHájos, N., Ledent, C. A., & Freund, T. F. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00287-1 · Cited by 421
Self-citationMarzo, V. D., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 394
Compton, D. M., Aceto, M. D. G., Lowe, J. A., III, & Martin, B. R. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12911-x · Cited by 357
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Metadata
- Authors
- Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F.
- Affiliations
- HUN-REN Institute of Experimental Medicine (HU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Freund, T. F.
- ORCID
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 16
- Issue
- 7
- Pages
- 1395-1398
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2027352187
- Cited by
- 354
- References
- 26
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 5 · 2023: 14 · 2022: 6 · 2021: 14 · 2020: 9 · 2019: 8 · 2018: 11 · 2017: 13 · 2016: 11 · 2015: 16 · 2014: 16 · 2013: 18 · 2012: 18
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Hungarian Scientific Research Fund
- National Institute of Mental Health (R01MH054671, MH54671)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- CB1 receptor, anxiety, CB1 knockout mice, SR141716A, cannabinoid receptor antagonists, elevated plus maze, locomotor behaviour
- MeSH terms
- Rimonabant, Animals, Anxiety, Exploratory Behavior, Motor Activity, Piperidines, Pyrazoles, Receptors, Drug, Mice, Knockout, Maze Learning, Receptors, Cannabinoid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
